Bionomics : • Operations Presentation

Bionomics - Corporate Presentation

November 2023

Developing treatments for patients with underserved CNS disorders

Nasdaq: BNOX

Safe Harbor Statement

Factors Affecting Future Performance

This presentation may contain "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC105, BNC101 and BNC375), its licensing agreement with MSD (known as Merck & Co., Inc., Rahway NJ, USA in the US and Canada) and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing arrangements, delays or difficulties associated with conducting clinical trials, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its expectations, projections or plans will be achieved. Actual results may differ from those expectations, projections or plans due to the risks and uncertainties inherent in Bionomics business and other risks described in Bionomics' filings with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward- looking statements as a result of developments occurring after the date of this presentation.

Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third party sources and Bionomics' own internal estimates and research. While we believe these third party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Corporate Presentation

2

As a reminder, I will be making some forward-looking statements so please take a moment to review the Safe Harbor Statement.

Targeting Common Neuropsychiatric Disorders of High Unmet Need

BNC210: Phase 3-Readyα7 Nicotinic Receptor Negative Allosteric Modulator Leads Pipeline

• Unique profile compatible with acute, as needed and chronic administration. Non-sedatingnon-habit-forming psychoactive profile,
• Potential to be the chronic treatment for PTSD in decades and the first acute, as-needed treatment for Social Anxiety Disorder with a non-sedating,non-habit-forming profile

Clinical and Regulatory Milestones Anticipated

• Sep'23: Positive topline data from placebo-controlled Phase 2b ATTUNE study of BNC210 in PTSD
• Sep'23: Successful FDA End-of-Phase 2 meeting with clear path forward to Phase 3 - validation of PREVAIL study dataset strength
• Q4'23 / Q1'24: Potential for first patient dosed in Phase 3 study of BNC210 in Social Anxiety Disorder

Partnerships and Collaborations Support Early-Stage Programs

• MSD partnership: MK-4334 in late Phase 1 targeting cognitive deficits in Alzheimer's and other CNS disorders
• Memorandum of understanding with EmpathBio for feasibility assessment of EMP-01 (MDMA derivative) & BNC210 for PTSD treatment
• Other partnering opportunities include preclinical assets targeting potassium (Kv) and sodium (Nav) ion channels

CNS = central nervous system; FDA = US Food and Drug Administration; MDMA =3,4-Methylenedioxymethamphetamine; MOU = Memorandum of Understanding; NAM = negative allosteric modulator; PTSD = Post-Traumatic Stress Disorder.

Corporate Presentation

3

Thank you Alan,

Despite the unfavorable markets, this last year has been a transformational for Bionomics.

We have successfully continued the development of BNC210, our lead asset which is an a7 nicotinic receptor NAM in the clinic for the treatment anxiety disorders and PTSD.

Building on earlier clinical, translational and formulation work, BNC210 administration in 2 separate Ph2 trials continues to supports its differentiated, non-

sedating, non-habit-forming anxiolytic and anti-depressive profile which is compatible with chronic and acute administration making it a first and best in-class molecule in its category with potential in multiple neuropsychiatric disorders.

In addition to reporting results from 2 Ph2 trials, we successfully met with the FDA during a EoPh2 meeting for SAD and we are in the tail end of preparations to start our first Ph3 as a company.

All this with a new management focused on nimble and focused operational model

One of our great strengths continues to be our strategic collaboration with Merck that not only validates our ion-channel targeting technology but also is a potential source of future non-dilutive capital through regulatory and clinical milestones in a partnership that is values around 500M USD.

We also continue exploring avenues to fully leverage our preclinical assets in the area of voltage gated channels including the Kv3 inhibitor which has garnered significant interest.

Next slide

Multi-Asset CNS Pipeline Led by Social Anxiety Disorder Program Entering Phase 3

FDA Fast Track Designations for Social Anxiety Disorder and PTSD

Program

Indication

Pre-Clinical

Phase 1

Phase 2

Phase 3

Status

	Social Anxiety Disorder		Completed
	(SAD)		EoP2 Mtg: 2H'23
BNC210	Post-Traumatic Stress		Enrollment
α7 receptor NAM	Disorder (PTSD)		Completed - Topline: Q3'23
	CNS Indication(s)		To be disclosed
	+MDMA derivative	MOU to explore combination treatment regimen	Feasibility assessment
BNC210	EMP-01 (PTSD)
Collaboration	2 candidates for Cognitive		Phase 1 safety & biomarker
Deficit in Alzheimer's		studies ongoing
α7 receptor PAM
Nav1.7/1.8 Inhibitors	Chronic Pain		Partnering Asset
Series Lead
Kv3.1/3.2 Activators	Cognitive Impairment		Partnering Asset
Series Lead
NAM = Negative Allosteric Modulator; PAM = Positive Allosteric Modulator.		FDA Fast Track designation
			Corporate Presentation 4

Our pipeline is shown here.

BNC210 is enjoys fast track designation in both PTSD and SAD is entering Ph3 development that could leave to separate NDA applications in the next 4-5 years.

Our pipeline and our partnerships positions as well for growth as a key player in the area of prevalent neuropsychiatric diseases with high unmet need

Next slide

BNC210: A Phase 3-Ready Best- and First-in-Classα7 Nicotinic Receptor Small Molecule NAM in Development for the Treatment of Neuropsychiatric Disorders

Unique and differentiated MoA

Clinically meaningful reduction

of anxiety in GAD & SAD - similar to benzodiazepines

*Profile based on a safety database of ~600 subjects.

Rapid (~60 min) and durable	Clinically meaningful reduction
(half-life4-5 hrs) anti-anxiety relief	of PTSD symptom severity with
Chronic administration for PTSD and other	treatment effects higher than
indications	SSRIs

Non-sedating,non-habit forming,	Fully developed internally, solid
not cognition impairing*	tablet formulation, strong IP
	protection

GAD: General Anxiety Disorder; MOA = Mechanism of Action; SAD: Social Anxiety Disorder; PTSD = Post-Traumatic Stress Disorder; SSRIs = Serotonin Selective Reuptake Inhibitors

Corporate Presentation

5

A few points on the unique nature of BNC210 which we belive has very good chances of becoming a game changing therapeutic in neuropsychiatry:

• BNC210 is a Ph3-ready novel best-andfirst-in class negative allosteric modulator of α7 nAChR for treatment of anxiety and stress-related disorders.
• BNC210 that has undergone extensive efficacy (anxiety and mood) and safety profiling in preclinical models and has an extensive safety database from 600 patients to date supporting a non-sedating and non-addicting,non-cognition impairing psychoactive profile
• BNC210 has shown clinical effects in 4 studies where acute administration has led to reduction of panic attacks and symptoms, reduction of anxiety in GAD and reduction of anxiety in SAD and reduction of symptom severity in PTSD.
• BNC210 is currently in development for underserved markets for million of PTSD

and SAD patients worldwide that have seen no new therapies in nearly two decades

• Finally, BNC210 enjoys a has strong patent coverage through late 2030's.
  Next slide

BNC210 in Post-Traumatic Stress Disorder

6

PTSD: A Chronic Psychiatric Disorder with Significant Unmet Need

Only 20-30% of PTSD patients achieve clinical remission on SoC SSRI therapy1

PTSD is a debilitating disorder that leads to social, occupational and interpersonal dysfunction. It involves flashbacks, intrusive thoughts and nightmares.

PTSD causes changes in cognition, mood, arousal and reactivity, and can ultimately affect work,

relationships, and ability to perform daily activities.

PTSD results from exposure to actual or threatened death, serious injury or sexual violence.

		BNC210's Advantages*
	BNC210	SSRIs / SNRIs	Ketamine	MDMA†
	Experimental	Experimental
No Withdrawal		X2,3		X4
Syndrome
No neurotoxicity or			X5,6	X7
other toxicity
No Cognitive or			X8	X9
Memory Impairment
No Suicidal Ideation/		X		X10
Suicide Risk

1. Lee DJ, et al. Depress Anxiety. 2016. 2. Fava GA, et al. Psychother Psychosom. 2015. 3. Fava GA, et al. Psychother Psychosom. 2018. 4. Barbui C, et al. CMAJ. 2009. 5. Kurdi MS, et al. Anesth Essays Res. 2014. 6. Dong C, et al. Toxicol Lett. 2013.

1. Sarkar S, et al. Curr Pharm Biotechnol. 2010. 8. Ward J, et al. J Clin Exp Neuropsychol. 2006. 9. Morgan CJ, et al. Addiction. 2012. 10. Wagner D, et al. Addiction. 2013. 10. Kim J, et al. Suicide Life Threat Behav. 2011.
   *Potential benefits based on analysis of data from separate studies and not on results that might have been obtained from head-to-head studies.
   † MDMA does not work as a monotherapy. MDMA has been explored in combination with CBT. BNC210 + MDMA combination therapy may reduce number of CBT sessions required during MDMA treatment.

Corporate Presentation

7

Shifting to the PTSD program.

• The indication itself is highly debilitating and affects patients ability to work, foster relationships, and to perform daily activities
• BNC210 has a favorable side effect profile compared to approved and emerging therapies for PTSD. SO far there is no indication of withdraw symptoms and addition potential, no impact on cognition and no risk of suicidality positioning BNC210 favorably compared to both approved such as SSRIs and experimental therapeutics such as ketamine and MDMA

Next slide

PTSD Represents a Significant Unmet Need and Market Opportunity

No newly approved pharmacotherapy in almost two decades

~21M

8% of adults

at some

~9M point in their lives

3.4%

~7M prevalence in adults

75% of adults

inadequately treated

U.S. Opportunity for BNC210

BNC210 could achieve

blockbuster status in US annual

peak sales in PTSD*

Unmet medical need to large patient population Advancement in care

Ability to potentially achieve large market share

Kilpatrick, D., et al., Journal of Traumatic Stress, 2013. Mayo LM, et al. Biol Psychiatry. 2020.

US Census Bureau. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html *Based on 3rd party (Bluestar BioAdvisors) independent market analysis.

Corporate Presentation

8

• PTSD is also highly prevalent: Approximately 21M people in the United States, or 8.1% of the population, suffer from PTSD at some point in their lives. The unmet need is significant with no new medications for PTSD have been approved in over two decades.
• This lack of new entrants means that BNC210 has the potential to capture a large share of the market with blockbuster potential

Next slide